CDEK
← All drugs Report issue

respiratory syncytial virus immune globulin intravenous

Trade name: respigam

Small moleculeapprovedOrphan Drug FDA

Approved

Jan 2, 1996

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1990s

  1. Sep 27, 1990

    Orphan Drug Designation

  2. Jan 2, 1996

    MedImmune — Earliest FDA Approval

  3. Jan 2, 1996

    MedImmune — NDA Organization

Indications

Approved for

Mechanism of action

Approval history

  • approvedJan 2, 1996

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • respigam
  • respigam
  • respiratory syncytial virus immune globulin intravenous
  • respiratory syncytial virus immune globulin intravenous
  • rsv-igiv

Organizations

Marketing (1)

OrganizationOrg typeRelationshipDate
MedImmuneFor profitNDAJan 2, 1996